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ABSTRACT
BACKGROUND: Compared with the resources expended developing, evaluating 
and making clinical decisions about prescribing medication, we know little about 
what determines whether people take it. Older adults are prescribed more 
medication than any other group. Poor adherence is a common reason for non-
response to medication. 
OBJECTIVES: To investigate cross-nationally the impact of demographic, 
psychiatric (including cognitive), physical health, behavioural and medication factors 
on adherence to medication in older adults.
METHODS: Researchers interviewed 3881 people over 65 who receive home 
care services using a structured interview at participants’ places of residence in 
eleven countries. The main outcome measure was the percentage participants not 
adherent to medication.
RESULTS: 12.5% (n= 456) of people reported they were not fully adherent to 
medication. Non-adherence was predicted by problem drinking (OR=3.6), not having 
a doctor review medication (OR=3.3), dementia (OR=1.4 for every one point 
increase in impairment), good physical health (OR=1.2), resisting care (OR=2.1) 
being married (OR=2.3) and living in the Czech Republic (OR=4.7) or Germany 
(OR=1.4). 
CONCLUSION: People, who screen positive for problem drinking and with 
dementia, often undiagnosed are less likely to adhere to medication. Therefore 
doctors should consider dementia and problem drinking when prescribing for older 
adults. Interventions to improve adherence in older adults might be more effective if 4
targeted at these groups. It is possible that medication review enhances adherence, 
by improving the patient-doctor relationship, or by emphasising the relevance of 
medications.
INTRODUCTION
Older adults receive more prescriptions per head than any other group
1, but 
may adhere to only 60% of medication
2. Compared with the resources expended 
developing, evaluating and making clinical decisions about prescribing medication 
for older adults, we know little about what determines whether patients actually take 
it. Adherence, defined as the extent to which a person's behaviour conforms to 
medical or health advice
3 determines response to treatment in all medical conditions.  
In North America, more than 10% of older peoples’ medical emergency admissions
and 25% of nursing home admissions
4,5 relate to medication non-adherence
6.
Factors previously associated with non-adherence include being male
7; less 
fear of illness, not living with a relative
8; adverse effects, poor instructions, patients’ 
disagreement with the need for treatment
9 and cost
10. Reasons older adults might be 
less adherent than younger adults include greater likelihood of cognitive deficits, 
poor physical health, polypharmacy and adverse effects. Conversely older adults 
may be more likely to adhere to medication, because of, for example lower rates of 
substance misuse. Some studies have excluded people with cognitive impairment so
may overestimate adherence in older people. Findings concerning the relationship of 
age with adherence have been inconsistent  e.g. improved adherence in people over 
50
11, decreased adherence in older age
12,13, greater adherence in patients aged 55-
64 years compared older and younger groups
14, and, in people over 65, no 5
difference in adherence between the younger and the oldest old
10. Trials of 
interventions to improve adherence so far have been disappointing
9,15. Knowing 
more about the associates of non-adherence in older adults may help develop and 
target measures to increase the proportion of medication actually taken, and 
therefore potentially to improve their effectiveness. 
Nearly four thousand older adults living in eleven countries took part in the 
AdHOC (Aged in Home Care) study. We used this data to carry out the first cross-
national study of adherence to medication, and to investigate the relationship of 
putative risk factors to adherence.
METHODS
Ethics permission was granted in all countries according to local regulation.
Setting
3881 adults ￿ 65 years of age who were receiving health or social community 
services in any setting participated in the AdHOC study. Table 1 gives eligibility 
criteria for health and social services in the countries studied
16.  The mean level of 
dependency of participants was lowest in the Nordic countries, the Netherlands and 
the Czech Republic, followed by England and Germany, and highest in Italy and 
France
16. Italy and the Czech Republic had the lowest levels of formal care 
provision, and the UK had the most.
Table 2 describes the population, numbers interviewed and refusal rates for 
each country. Each national study organiser selected an area judged to be 6
representative of the country. Trained interviewers approached all potential 
participants in these areas for interview. Methodology is described by the AdHOC 
group
16. We included AdHOC study participants who were taking prescribed 
medication. Medication data was available for 3803(98.0%) of people interviewed for 
the AdHOC study, of whom 3643 (94.0%) were taking prescribed medication.
Data Collection
We recorded patient information using the interRAI (www.interrai.org) version 
2.0 Minimum Data Set for Home Care (MDS-HC), which is a structured, 
standardised, assessment instrument with adequate psychometric properties
17. The 
MDS-HC has been used for epidemiological research in several participating 
countries
16. Prior to data collection, the instrument was translated, back-translated 
and examined for face validity in the language of each participating country.  
We used adherence as our main outcome measure, and divided it into three 
bands: 100%, above 80% and below 80% adherence. We employed this high cut 
point for adherence, because we expected high rates of non-adherence in this frail, 
elderly study population and because these thresholds have been used previously
18. 
Interviewers asked the participant (or their carer if the person was cognitively 
impaired or the carer administered the medication) open questions about their 
adherence such as “What medications have you taken today/ yesterday?” to 
ascertain reported adherence over the last seven days.  They checked responses 
with medication available and prescriptions. We also analysed sociodemographic 7
data, and the following cognition, psychiatric and physical health and medication 
details which were collected at interview. 
Cognitive measure - the MDS Cognitive Performance scale (CPS) score is a seven 
point scale measuring cognitive impairment (0 intact, 6 very severely impaired). A 
CPS score of two indicates dementia
19. The mean MMSE score for those who score 
two is 19; those who score 3 is 15; those who score 4 is 7; those who score 5 is 5 
and those who score 6 is 0
19.  
Behavioral symptoms - Carers were asked about presence of wandering (moving 
with no rational purpose, seemingly oblivious to needs or safety), verbally abusive 
behaviour  (threatening,  screaming  at,  or  cursing  others),  physically  abusive 
behaviour  (hitting,  shoving,  scratching,  sexually  abusing  others),  socially 
inappropriate  behaviour  (making  disruptive  sounds,  noisiness,  screaming,  self-
abusing acts, sexual behavior or disrobing in public, smearing or throwing food or 
faeces,  hoarding,  rummaging  through  other's  belongings) and  resisting  of  care
(resisting  treatment,  ADL  assistance,  eating  or  changes  in  position)  in  the  last  3
days, and each item was scored as 0 (behaviour absent), 1 (behaviour present but 
easily altered with current interventions) and 2 (present and not easily altered). This
behavioural  scale  has  been  validated  against  the  Alzheimer's  disease  Patient 
Registry Physician Behavior checklist scores, with a correlation coefficient of 0.5
20. 
Over 2 years the MDS behaviour domain (Effect Size (ES) = 0.058) was comparable 
to  the  Research  Behaviour  Checklist  (ES  =  0.065).  These  data  demonstrate 
reasonable criterion validity of the MDS behavior rating scales
20.8
Psychiatric morbidity – Participant were asked whether they had a psychiatric or 
dementia diagnosis, or had delirium in the last seven days. 
The MDS-Depression Rating Scale Score (DRS) was used with a cut off point of 2/3
for caseness. It has been validated against the Hamilton Depression Rating Scale 
and the Cornell Scale, a measure of depression in dementia, and has high sensitivity 
(94% and 78% respectively) and specificity (72% and 77% respectively)
21. It 
compared favourably with the Geriatric Depression Scale when tested against 
psychiatric DSM-IV diagnosis
21.
Alcohol misuse - Interviewees screened positive for alcohol misuse if in the last 90 
days, they had felt the need or were told to cut down on drinking, others were 
concerned about their drinking; they had a drink on waking to steady their nerves, or 
they had been in trouble due to drinking.
Physical functioning – Physical functioning was measured by using the MDS 
Activities of Daily Living Hierarchy (MDS-ADL)
22 and Instrumental Activities of Daily 
Living index (MDS-IADL) scores
23. In addition, we recorded scale scores for hearing 
(0-3) and vision (0-4), with 0 representing no impairment.
Medication – Participants were asked about number of medications taken. Four 
classes of psychotropic drugs (antidepressants, anxiolytics, hypnotics and 
antipsychotics) were coded as prescribed or not prescribed in the last seven days. 9
Participants were asked if their medication had been reviewed by a doctor in the last 
six months. 
Statistical methods
Because of the high number of statistical tests employed, we used a 
significance level of p<0.01 for univariate analyses. We calculated the proportion of 
people in the three categories of adherence and made cross-national comparisons 
using ANOVA and Tukey HSD post hoc tests to indicate which differences were 
significant. We determined which countries were significantly different to at least 7 
and at least 8 others and reported this. We employed ￿
2-tests, and univariate 
analyses of variance as appropriate to compare proportions and means of each 
variable studied. We used a logistic regression to determine which factors were 
independent predictors of non-adherence, and calculated odds ratios (OR) and 
confidence intervals (CI). The independent variables we included were: age; gender; 
country of residence; living alone; living with a carer; living in residential/nursing 
home; marital status; amount of formal and informal care received; scales scores for 
hearing, vision, wandering, resisting care, verbally or physically abusive or socially 
inappropriate behaviour; score and caseness on CPS and DRS; screening positive 
for alcohol abuse; dementia diagnosis; any psychiatric diagnosis; ADL and IADL 
scale scores; number of medications; receipt of antidepressants, anxiolytics, 
antipsychotics, hypnotics; occurrence of medication review in the last six months.
RESULTS
The overall response rate for people approached was 79.7% (n=3878). 10
Cross-national Variation (table 3)
12.5% (n= 456) of people reported they were not fully adherent to medication. The 
median number of medications prescribed was six, and 82.4% (n=3019) of people 
interviewed had received a medication review in the previous six months. Rates of 
non-adherence were highest in the Czech Republic and Germany.
Univariate analysis
Factors associated with reduced adherence on univariate analysis are 
reported in table 4.  Those who were not currently married, lived alone, were cases 
or scored higher on the CPS or DRS scales, were diagnosed with dementia or 
delirium, were cases on the alcohol screen, exhibited behavioural problems of 
resisting care or wandering, and who had not had their medication reviewed by a 
doctor in the last six months were all less likely to be adherent. While people at all 
stages of dementia were less adherent than those without dementia, adherence 
rates demonstrated an inverse U-shaped relationship to CPS score, with lowest 
adherence in moderate dementia (figure 1). One way ANOVA demonstrated that 
adherence rates varied significantly with CPS score (F=7.32, d.f.=6; p<0.001), Tukey 
HSD post hoc tests indicated that the significant differences were between intact 
cognition and moderate (mean difference = 0.051, p<0.001) and moderately severe
(mean difference = 0.076, p<0.001) impairment.11
Logistic Regression (table 5)
As shown in table 5, non-adherence was predicted by screening positive for 
problem drinking, greater cognitive impairment, resisting care, being unmarried, 
lesser ADL impairment, no medication review in the last six months, and living in the 
Czech Republic  or Germany. The overall model had a -2log likelihood of 766.250, 
cox and snell R
2 of 0.051, andNagelkerke R
2of 0.208.
DISCUSSION
Adherence rates reported are higher than in previous studies, and did not 
decline with age.  This might be because earlier studies have examined 
discontinuation rates, but we measured adherence to established medication 
regimes. Most older adults interviewed adhered to medication, even when 
experiencing psychiatric illness, physical morbidity, or cognitive decline, and despite 
taking on average six different types of medication daily. Problem drinking, dementia, 
no medication review in the last six months, resisting care and poorer ADL 
functioning predicted non-adherence. 
Decreased adherence was associated with dementia, and with resisting care, 
which often occurs in people who have limited insight into their dementia. The non-
linear relationship between adherence to medication and cognitive function, with 
adherence lowest in those with moderate impairment, appears to explain previous 12
conflicting research findings. Perhaps participants with mild cognitive impairments 
are more aware of their impairment and use systems such as pill boxes to help 
remind them to take their medication. This suggests practitioners could improve 
treatment adherence by tailoring interventions to the degree of cognitive impairment.
More people with severe dementia live with others who act as carers prompting or 
administering medication, due to their greater care needs. This could explain their 
increased adherence compared with people with moderate dementia, who are more 
likely to live alone. Results suggest that those who live alone with significant 
cognitive impairment are most likely to be non-adherent. Non-adherence could be a 
significant factor determining when institutionalisation is required.
Country of Residence
Living in Germany or the Czech Republic predicted non-adherence. In the 
Czech Republic this might relate to the lower levels of formal service provision, either 
because medication was monitored less often or because good relationships 
between the care recipient and provider could foster good adherence. This cannot 
be the only factor influencing results, however, because Germany had similar levels 
of service provision to other countries, but lower adherence. 
Measurement biases between raters from different countries could have 
accounted for part of the association of adherence with country of residence, but 
there could also be true national differences, over and above confounding factors, in 
the likelihood of people adhering to medication. In the Czech Republic, the older 
people might have felt less able to approach doctors to discuss medication 13
problems, because of their experiences during the communist era of doctors as 
strong hierarchical figures. Medical staff in the Czech Republic have particularly high 
caseloads, and are perhaps less accustomed to asking patients about adherence. 
Many Czech older people are economically disadvantaged, but they are subject to 
the same prescription charges as younger adults. For economic reasons, older 
drugs, which are less effective and have more side effects, are more likely to be 
used than in Western Europe
24. 
We did not study the association of non-adherence with the cost of 
medication, but people pay more for their medication in Germany, on average, than 
in the other countries studied
25, and it is possible that this could account for the 
higher rates of non-adherence in that country. This is consistent with research in the 
USA finding that many elders, most of whom pay for their own medication, are 
unable to afford to cash their prescriptions
26.
Possible Interventions
Review of medication by a doctor in the last six months was associated with 
improved adherence. Attending for regular medication review might reflect an 
obedient medicalised individual who is also more compliant with medication. It is also 
possible that a medication review enhances adherence, by improving the patient-
doctor relationship, or by emphasising the relevance of medications. Polypharmacy 
is common in older people
27, and it has been suggested that reviewing and possibly 
reducing the number of medications might help adherence
28.  Number of 14
medications was not a significant predictor of non-adherence in our study. This may 
be explained by the “intent to treat” effect of doctors prescribing more medications to 
patients they judge more likely to take them. Our results suggest that treatment of 
problem drinking and dementia might also improve adherence. This presents a 
difficulty, because effective treatment programmes often include medication.
Currently the evidence for interventions specifically developed to improve 
adherence is not convincing 
9,15. We suggest that the failure of studies in this area to 
differentiate between people with and without cognitive impairment may have limited 
the effectiveness of the interventions. Perhaps simpler interventions are useful 
where cognitive deficits are present, but in unimpaired older people, as has been 
suggested
15 and our group has piloted
29 ambivalence and attitudes to medication 
need addressing. 
Strengths and Weaknesses of the Study
This is the largest ever study of adherence.  We compared rates of 
adherence cross-nationally, investigated most postulated associations for non-
adherence and considered whether they are independent predictors. To collect 
adherence data, we combined subjective and objective measurements of adherence. 
This method had good face validity and does not change behaviour, unlike, for 
example, electronic pill boxes, although self-report measures have been found to 
significantly overestimate adherence rates
30. We did not have data about use of 
reminder systems such as pill boxes. 15
The sample consisted of those who had home care services and was 
therefore not random. It is likely that people who refuse services are the least 
adherent group, and they were not sampled. There were higher refusal rates in 
Finland, Sweden, the Netherlands and UK.  Those who refused to be interviewed 
may have been less adherent, so adherence could have been over-estimated. 
Carers were asked about non-adherence where they were responsible for 
administering the medication, but they may have been reluctant to report non-
adherence if they perceived tablet intake as their responsibility. Therefore although 
the adherence in the dementia group was poor, it might still have been an 
underestimate. 
Conclusion
Doctors may increase adherence in older people by reviewing medication 
every six months, and by considering dementia when prescribing. Improved 
detection of dementia and alcohol use disorders might have a positive impact on 
adherence. Interventions developed to improve adherence might be more effective if 
adapted for and targeted at specific populations, for example people with moderate 
cognitive impairment. 16
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TABLES
Figure 1: Relationship between rates of non-adherence to medication and CPS 
score (measure of cognitive impairment where 0= no impairment and 6 = very 
severe impairment)
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Table 1: Characteristics of services of home care agencies by country
16 (CZ=Czech Republic)
CZ  Denmark Finland France
Health   Social
care        care
Germany Iceland Italy NL Norway Sweden UK
Administrative characteristics:
 Eligibility criteria: 
   Physical function level
   Cognitive level                                     
   Presence of psychiatric diseases     
   Family support level
   Means tested  
   Medical prescriptions 
 Comprehensive geriatric assessment
 Team meetings 
   Never
   Sometimes 
   Always 
 GP participating in team meetings    
 Participation of informal carer            
 Multidisciplinary team approach        
 Case manager
 Administrative status
Profit              Non profit     
Public
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Financial characteristics:
Public payment/compulsory insurance   
Personal contribution (copayment)
Contribution by others (municipalities, charities, 
others)      
￿
￿
*
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Table 2: Characteristics of each site including national population. % aged 
over 65, sampling and refusal rate
16 
Country of 
Residence
National 
Population 
(millions)
%65+
in 
country
No. people in 
study area
(thousands)
%65+ in 
study 
area
Study sample 
(all 65+) 
No.
Refusal 
rate (%)
Germany 82.26 16.6 655 21.2 607 4
CZ 10.27 13.8 93.9 19.9 430 18
Denmark 5.37 14.8 71.8 16.5 401 10
England 49.14 15.9 241.6 15.8 290 39
Finland 5.19 15.2 73 14.6 187 57
Netherlands 16.20 13.9 735 12.0 197 49
France 59.20 15.9 260 15.5 311 0
Sweden 8.59 17 60.0 22.4 250 38
Norway 4.52 15 128 16 388 7
Italy 57.61 18.6 215 16.7 412 1
Iceland 286 13.7 35.9 14.2 405 323
Table 3: Adherence, number of medications prescribed and proportion of people 
receiving six-monthly medication reviews in the participating countries
Country of 
Residence
No. (%) fully 
adherent to 
medication
No. (%) at 
least 80% 
adherent to 
medication
No. (%) 
< 80% 
adherent to 
medication
Median 
no. of 
prescribed 
drugs
No. (%) of people 
who had 
medication review 
in last 6 months
Germany 417 (83.1%)** 43 (8.6%)** 42(8.4%)** 5* 456 (82.5%)
CZ 280 (66.5%)** 116 (27.6%)** 25 (5.9%)** 7* 378 (88.3%)
Denmark 324 (87.1%) 36 (9.7%) 12(3.2%) 6* 283 (70.8%)*
UK 230 (82.7%) 41 (14.7%) 7(2.5%) 5 126 (43.6%)**
Finland 161 (90.4%) 14 (7.9%) 3(1.7%) 8* 146 (78.1%)
Netherlands 168 (88.0%) 20 (10.5%) 3(1.6%) 5 157 (79.3%)
France 290 (96.0%) 8 (2.6%) 4(1.3%) 6 163 (94.8%)
Sweden 215 (90.0%) 21 (8.8%) 3(1.3%) 6 188 (78.0%)
Norway 338 (92.6%) 23 (6.3%) 4(1.1%) 4* 366 (94.8%)
Italy 388 (97.2%) 8 (2.0%) 3(0.8%) 4* 392 (96.1%)
Iceland 376 (94.9%) 17 (4.3%) 3(0.8%) 7 364 (90.3%)
TOTAL 3187 (87.5%) 347 (9.5%) 109(3.0%) 6 3016 (82.4%)
** denotes statistically significant differences between country indicated and at least 8/10 
other countries, and *denotes statistically significant differences with at least 7/10 other 
countries using Tukey’s HSD test.24
Table 4: Association of Variables Studied with Adherence
No. (%)/ mean(sd) of people adherent:
100% of time 
(n=3187)
> 80% of time 
(n=347)
<80% of time 
(n=109)
@F /￿
2 Significa
nce
(p)
Age 82.15 (7.3) 81.93 (7.5) 82.26 (7.6) F=0.159 0.853
Male 855 (26.8%) 75 (21.6%) 24 (22.0%) ￿
2=5.411 0.067
Married 795 (24.9%) 56 (16.1%) 14 (12.8%) ￿
2=20.78 <0.001**
Living in care home 85 (2.7%) 15 (4.4%) 5 (4.6%) ￿
2=3.958 0.138
Living alone 1871 (58.7%) 259 (74.6%) 72 (66.1%) ￿
2=34.70 <0.001**
Formal care (hrs/week) 5.54 (12.0%) 5.21 (8.9%) 7.15 (10.8%) F=1.166 0.312
Case (2+) on CPS  857(26.9%) 128(36.9%) 56(51.4%) ￿
2=43.94 <0.001**
CPS score 1.1(1.6) 1.2(1.3) 1.9(1.7) F=14.94 <0.001**
Psychiatric diagnosis 276(8.7%) 41(11.8%) 14(12.8%) ￿
2=5.651 0.059
DRS score 1.01 (2.0) 1.7 (2.2) 1.6(2.6) F=19.236 <0.001**
Case on DRS 500(15.7%) 103(29.7%) 24(22.0%) ￿
2=44.83 <0.001**
Dementia diagnosis 401(12.6%) 44(12.7%) 26(23.9%) ￿
2=11.91 0.003*
Alcohol screen  54(1.7%) 9(2.6%) 8(7.3%) ￿
2=18.41 <0.001**
Delirium in last week 189(5.9%) 25(7.2%) 16(14.7%) ￿
2=14.14 0.001*
No. Impaired ADLs 2.7 (3.0) 2.3(2.6) 2.7 (2.7) F=2.610 0.074
No. Impaired IADLs 4.4 (2.2) 4.1 (2.0) 4.5(2.1) F=1.241 0.289
Vision 0. 6(1.0) 0.6 (1.0) 0. 6 (0.8) F=0.211 0.810
Hearing 0.5  (0.7) 0.5 (0.8) 0.5 (0.8) F=0.208 0.812
Verbally abusive 0.0 (0.2) 0.0 (0.2) 0.1 (0.3) F=1.920 0.14725
Physically abusive 0.0 (0.1) 0.0(0.0) 0.0 (0.2) F=1.634 0.195
Socially disruptive  0.0 (0.2) 0.0 (0.2) 0.1 (0.3) F=3.427 0.033
Resisting care 0.0 (0.2) 0.1 (0.3) 0.2 (0.5) F=28.80 <0.001**
Wandering 0.0 (0.2) 0.0 (0.2) 0.1 (0.4) F=10.48 <0.001**
No. meds  5.7 (2.7) 6.0 (2.5) 5.3 (2.6) F=3.714 0.024
Doctor review in last 6 
months
2573(84.2%) 262(76.2%) 66(61.7%) ￿
2=48.13 <0.001**
Antipsychotic 215(6.8%) 27(7.8%) 11(10.1%) ￿
2=2.226 0.329
Anxiolytic 399(12.5%) 59(17.0%) 9(8.3%) ￿
2=7.712 0.021
Hypnotic 675(21.2%) 77(22.2%) 14(12.8%) ￿
2=4.726 0.094
Antidepressant  503(15.8%) 38(11.0%) 18(16.5%) ￿
2=5.752 0.056
**=p<0.001; *=p<0.01
@ F statistic indicates test values for univariate analysis of variance; ￿
2 
indicates test statistic for chi-squared test. Degrees of freedom = 2 for all tests shown
CPS= cognitive performance scale; ADL= activities of daily living ; IADL= instrumental 
activities of daily living; DRS = Depression rating scale26
Table 5: Results of Logistic Regression (p<0.05 in bold)
95.0% C.I.for 
EXP(B)
B S.E. Wald df Sig. Exp(B)
Lower Upper
gender -.052 .274 .036 1 .849 .949 .555 1.624
age .007 .016 .171 1 .679 1.007 .976 1.038
Living alone .444 .318 1.955 1 .162 1.559 .837 2.906
nursing/ residential 
home resident
.090 .534 .028 1 .867 1.094 .384 3.112
Resident carer? .121 .369 .107 1 .743 1.129 .547 2.328
Being unmarried .843 .387 4.750 1 .029 2.323 1.089 4.956
formal care (hours) -.004 .008 .292 1 .589 .996 .981 1.011
S
o
c
i
o
d
e
m
o
g
r
a
p
h
i
c
 
f
a
c
t
o
r
s
 informal care (hours) .006 .004 2.494 1 .114 1.006 .999 1.013
Lesser ADL impairment .166 .065 6.567 1 .010 1.181 1.040 1.341
Iadl score -.045 .081 .308 1 .579 .956 .815 1.121
Vision .088 .126 .492 1 .483 1.092 .854 1.398
hearing .294 .160 3.386 1 .066 1.342 .981 1.837
cognitive impairment (for 
each point increase in 
CPS score)
-.325 .136 5.755 1 .016 1.4 1.1 1.8
CPS casenesss -.319 .410 .605 1 .437 .727 .325 1.624
Screening positive for 
problem drinking
-1.279 .482 7.046 1 .008 .278 .108 .71627
Psychiatric diagnosis -.095 .352 .073 1 .787 .909 .456 1.814
DRS caseness .496 .487 1.035 1 .309 1.642 .632 4.268
DRS score -.084 .085 .982 1 .322 .920 .779 1.085
Dementia diagnosis .222 .305 .527 1 .468 1.248 .686 2.270
Wandering -.316 .306 1.064 1 .302 .729 .400 1.329
Verbal abuse .156 .395 .156 1 .693 1.169 .539 2.538
Physical abuse -.007 .811 .000 1 .993 .993 .203 4.865
Socially inappropriate -.121 .497 .059 1 .808 .886 .334 2.350
B
e
h
a
v
i
o
r
a
l
 
p
r
o
b
l
e
m
s
:
Resisting care -.731 .280 6.802 1 .009 .481 .278 .834
No. medications .051 .044 1.328 1 .249 1.052 .965 1.147
antipsychotics -.251 .369 .462 1 .497 .778 .378 1.604
Anxiolytics .477 .402 1.409 1 .235 1.612 .733 3.544
Antidepressants -.243 .312 .605 1 .437 .785 .426 1.446
Hypnotics .208 .322 .416 1 .519 1.231 .655 2.315
M
e
d
i
c
a
t
i
o
n
:
No medication review in 
last 6 months
-1.193 .239 24.881 1 .000 3.3 2.1 5.3
Czech Republic -1.540 .664 5.373 1 .020 4.7 1.3 17.2
Denmark -.147 .342 .184 1 .668 .863 .441 1.689
Finland .062 .287 .047 1 .828 1.064 .606 1.867
France .021 .251 .007 1 .933 1.021 .624 1.671
Germany -.333 .129 6.635 1 .010 1.4 1.1 1.8
Iceland .112 .142 .622 1 .430 1.119 .847 1.478
L
i
v
i
n
g
 
i
n
:
Italy .053 .127 .177 1 .674 1.055 .823 1.35128
Norway .038 .089 .186 1 .666 1.039 .873 1.237
Sweden .038 .086 .197 1 .657 1.039 .878 1.229
UK  .008 .067 .014 1 .905 1.008 .884 1.149